Predicting if Lung Cancer Will Relapse-The Role of Neutrophil/Lymphocyte Ratio.

Q1 Medicine Hematology/ Oncology and Stem Cell Therapy Pub Date : 2023-01-17 DOI:10.1016/j.hemonc.2021.08.003

Abigail Chan, Søren Bentzen, Amit Rout, Kenneth Miller

{"title":"Predicting if Lung Cancer Will Relapse-The Role of Neutrophil/Lymphocyte Ratio.","authors":"Abigail Chan, Søren Bentzen, Amit Rout, Kenneth Miller","doi":"10.1016/j.hemonc.2021.08.003","DOIUrl":null,"url":null,"abstract":"Objective/background: Baseline neutrophil/lymphocyte ratio (NLR), a surrogate marker for systemic inflammation and immunosuppression, is a well-studied prognostic marker in non-small cell lung cancer (NSCLC). This study tests if interim NLR is prognostic in NSCLC patients in remission.Methods: This single-center, retrospective cohort study analyzed 131 NSCLC patients treated from 2010 to 2015 who achieved complete remission. NLR was calculated at baseline and from the first available blood sample during remission. Kaplan-Meier estimates of overall survival (OS) and time to recurrence were compared using the log-rank test for trend. Multivariable analysis was conducted using the Cox proportional hazards model.Results: Of the 131 cases, 63 had subsequently recurred at the last follow-up. The mean age was 64 ± 10 years. Patients with stage I (35%), II (24%), and III (41%) were included. Histology were adenocarcinoma (60%), squamous cell (33%), and unspecified (7%). The majority of patients were smokers. For the univariate analysis interim NLR was binned into tertiles, NLR < 2, 2-4.08, and > 4.08. Of those with an interim NLR > 4.08, prognosis and recurrence risk were higher. In the multivariable analysis, remission NLR was strongly prognostic for OS ( p < .001) as did patient's age ( p = .002), but not stage, race, sex, and baseline NLR.Conclusions: Our study found that interim NLR, obtained in remission, was strongly prognostic for OS and recurrence.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"16 2","pages":"158-161"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology/ Oncology and Stem Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.hemonc.2021.08.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

Objective/background: Baseline neutrophil/lymphocyte ratio (NLR), a surrogate marker for systemic inflammation and immunosuppression, is a well-studied prognostic marker in non-small cell lung cancer (NSCLC). This study tests if interim NLR is prognostic in NSCLC patients in remission.

Methods: This single-center, retrospective cohort study analyzed 131 NSCLC patients treated from 2010 to 2015 who achieved complete remission. NLR was calculated at baseline and from the first available blood sample during remission. Kaplan-Meier estimates of overall survival (OS) and time to recurrence were compared using the log-rank test for trend. Multivariable analysis was conducted using the Cox proportional hazards model.

Results: Of the 131 cases, 63 had subsequently recurred at the last follow-up. The mean age was 64 ± 10 years. Patients with stage I (35%), II (24%), and III (41%) were included. Histology were adenocarcinoma (60%), squamous cell (33%), and unspecified (7%). The majority of patients were smokers. For the univariate analysis interim NLR was binned into tertiles, NLR < 2, 2-4.08, and > 4.08. Of those with an interim NLR > 4.08, prognosis and recurrence risk were higher. In the multivariable analysis, remission NLR was strongly prognostic for OS ( p < .001) as did patient's age ( p = .002), but not stage, race, sex, and baseline NLR.

Conclusions: Our study found that interim NLR, obtained in remission, was strongly prognostic for OS and recurrence.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

预测肺癌是否复发——中性粒细胞/淋巴细胞比值的作用。

目的/背景:基线中性粒细胞/淋巴细胞比率(NLR)作为全身性炎症和免疫抑制的替代指标，是非小细胞肺癌(NSCLC)的预后指标。这项研究测试了中期NLR对缓解期非小细胞肺癌患者的预后是否有影响。方法:这项单中心、回顾性队列研究分析了2010年至2015年接受治疗的131例完全缓解的非小细胞肺癌患者。NLR是在基线和缓解期间第一次可用的血液样本中计算的。Kaplan-Meier估计的总生存期(OS)和复发时间使用log-rank检验进行趋势比较。采用Cox比例风险模型进行多变量分析。结果:131例患者中，63例在末次随访时复发。平均年龄64±10岁。包括I期(35%)、II期(24%)和III期(41%)患者。组织学为腺癌(60%)、鳞状细胞癌(33%)和未明确的(7%)。大多数患者是吸烟者。对于单因素分析，中期NLR被分成三组，NLR < 2、2-4.08和> 4.08。中期NLR > 4.08的患者预后和复发风险较高。在多变量分析中，缓解期NLR和患者年龄(p = 0.002)是OS的重要预后因素(p < 0.001)，但与分期、种族、性别和基线NLR无关。结论:我们的研究发现，在缓解期获得的中期NLR对OS和复发有很强的预后作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hematology/ Oncology and Stem Cell Therapy Medicine-Hematology

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

27 weeks

期刊介绍： Hematology Oncology and Stem Cell Therapy is an international, peer-reviewed, open access journal that provides a vehicle for publications of high-quality clinical as well as basic science research reports in hematology and oncology. The contents of the journal also emphasize the growing importance of hematopoietic stem cell therapy for treatment of various benign and malignant hematologic disorders and certain solid tumors.The journal prioritizes publication of original research articles but also would give consideration for brief reports, review articles, special communications, and unique case reports. It also offers a special section for clinically relevant images that provide an important educational value.